27 November 2024 - A Phase 1/2 trial in patients with relapsed or resistant acute leukaemias is on-going. ...
26 November 2024 - 26, 2024-- Exelixis today announced that the US FDA has notified the company that the supplemental new ...
26 November 2024 - Satsuma Pharmaceuticals and its corporate parent Shin Nippon Biomedical Laboratories are pleased to announce that the ...
26 November 2024 - Resubmission addresses questions raised in January 2024 complete response letter. ...
26 November 2024 - To potentially include adolescents and antibody persistence up to two years. ...
26 November 2024 - PDUFA target action date extended by three months to 27 March 2025. ...
25 November 2024 - PDUFA date set for 23 March 2025. ...
25 November 2024 - Intellia Therapeutics today announced that the US FDA has granted regenerative medicine advanced therapy designation to nexiguran ...
18 November 2024 - The extent to which patients with cancer are willing to accept uncertainty about the clinical benefit of ...
18 November 2024 - Cancer care stands at a critical juncture where the urgency of rapid drug approvals must be balanced ...
25 November 2024 - Imkeldi marks Shorla Oncology’s fourth FDA Approval. ...
27 November 2024 - AOP Orphan Pharmaceuticals announced that the US FDA has granted regulatory approval for Rapiblyk (landiolol) in the ...
25 November 2024 - Regulatory submission supported by Phase 3 head to head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, ...
23 November 2024 - Many appear cautiously optimistic about Trump’s intended pick. ...
21 November 2024 - Potential first and only DHE auto-injector for tough-to-treat migraines and cluster headaches. ...